✦ LIBER ✦

Efficiency and Tolerance of Aranose Combinations with Cisplatin and Gemcitabine in Experimental Lung Cancer

✍ Scribed by V. S. Pokrovsky; N. A. Lesnaya; V. I. Romanenko; E. M. Treshalina

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 265 KB
Volume: 148
Category: Article
ISSN: 0007-4888
DOI: 10.1007/s10517-010-0850-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacology of the paclitaxel–cisplatin

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

Combination of low-dose cisplatin and ge

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

✍ J. Feliu; G. Martín; C. Madroñal; A. Rodríguez-Jaráiz; J. Castro; A Rodríguez; T 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 189 KB

Concurrent gemcitabine and cisplatin com

Concurrent gemcitabine and cisplatin combined with 3D conformal radiotherapy for stage III non-small cell lung cancer

✍ Qinghua Ke; Guoquan Fu; Yaowu Bian; Daiwen Jiang; Jiyuan Yang 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 313 KB

A study of the combination of gemcitabin

A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule

✍ H. Kunikane; Y. Kurita; K. Watanabe; A. Yokoyama; K. Noda; Y. Fujita; S. Yoneda; 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 48 KB

Phase II study of a gemcitabine and cisp

Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

✍ Jae Hong Seo; Sang Cheul Oh; Cheul Won Choi; Byung Soo Kim; Sang Won Shin; Yeul 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 265 KB

Combination chemotherapy with cisplatin

Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer

✍ F. Figoli; A. Veronesi; M. G. Trovo; D. Errante; M. Della Valentina; V. Zagonel; 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 447 KB

A total of 52 consecutive, previously untreated patients with small-cell lung cancer (SCLC) were scheduled to receive six cycles of a combination of etoposide (75 mg/m2 per day) and cisplatin (20 mg/m2 per day), each cycle given over 5 consecutive days. In all, 28 patients had extensive disease (ED)